 The COVID-19 pandemic has caused an increase in mucormicosis cases in India due to inappropriate glucocorticoid use. This is especially true for those who have uncontrolled diabetes mellitus or are admitted to the ICU. Additionally, older age, rhinoorbital cerebral involvement and intensive care unit admission are all associated with higher mortality rates. Sequential antifungal drug treatment can improve mucormicosis survival. This article was authored by Atul Patel, Ritesh Ugarwal, Shiva Prakash M. Rudramurthy and others.